Last $12.07 USD
Change Today 0.00 / 0.00%
Volume 1.2M
NKTR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

John Nicholson

Chief Financial Officer and Senior Vice President, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

62$1,662,211
As of Fiscal Year 2013

Background*

Mr. John Nicholson has been the Chief Financial Officer and Senior Vice President at Nektar Therapeutics since December 10, 2007. Mr. Nicholson has more than 25 years of experience in the pharmaceutical industry and served as Senior Vice President of Nektar Therapeutics. He served as Senior Vice President of Corporate Development and Business Operations of Nektar Therapeutics since 2007 and also served as its Principal Accounting Officer until April 2008. Prior to Nektar, ...

Read Full Background

Corporate Headquarters*

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

BBA
The University of Toledo

Other Affiliations*

Annual Compensation*

Salary$524,264
Total Annual Compensation$524,264

Stock Options*

All Other Compensation$12,112
Exercisable Options963,997
Exercisable Options Value$3,275,924
Unexercisable Options224,003
Unexercisable Options Value$609,906
Total Value of Options$3,885,830
Total Number of Options1,188,000

Total Compensation*

Total Annual Cash Compensation$812,376
Total Short Term Compensation$524,264
Other Long Term Compensation$12,112
Total Calculated Compensation$1,662,211
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $12.07 USD 0.00

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer, Senior Vice President of Finance, Treasurer and Director
Theravance Inc.
$515.4K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$590.6K
Peter S. Greenleaf Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
Sucampo Pharmaceuticals, Inc.
--
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.